Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. leonid

LEONID SIGNED

Lung cancEr fusiOn geNes: a new dIagnostic Device

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 LEONID project word cloud

Explore the words cloud of the LEONID project. It provides you a very rough idea of what is the project "LEONID" about.

hospitals    specificity    company    labs    samples    personal    cancer    diagnostic    power    ivd    treatment    multiplex    biomarkers    ehr    clinical    pharmacogenetics    time    assay    pgx    inhibitors    molecular    alk    experimental    proprietary    running    cheapest    business    distributors    detects    validation    perform    fusion    reduce    eml4    panel    bimind    software    ready    oncology    patients    fusions    secondary    geneticlab    interpretation    vitro    ret    kit    complementary    least    device    rearrangements    tests    450    predictive    laboratories    unknown    performance    diatech    ihc    feasibility    speed    pathology    losing    variants    easiest    first    tyrosin    robustness    solution    specialized    detection    medium    laboratory    fish    of    lung    sensitivity    85    reproducibility    entrance    hands    scope    extended    supporting    leonid    passed    throughput    customers    standardized    data    combination    error    standards    nanostring    ce    saving    guarantee    avoiding    kinase    boost    genes    verification    fastest    rate    extend    ros1    standardization    expertise   

Project "LEONID" data sheet

The following table provides information about the project.

Coordinator		 DIATECH PHARMACOGENETICS SOCIETA A RESPONSABILITA LIMITATA 

Organization address
address: VIA SILONE 1 BIS
city: JESI
postcode: 60035
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website http://leoniddiatech.blogspot.it
 Total cost 1˙704˙000 €
 EC max contribution 1˙704˙000 € (100%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DIATECH PHARMACOGENETICS SOCIETA A RESPONSABILITA LIMITATA IT (JESI) coordinator 1˙465˙438.00
2    BIMIND SAS DI MARINELLI MARCO VICO MAURIZIO EC IT (JESI) participant 155˙000.00
3    GENETICLAB S.R.L. IT (Pordenone) participant 83˙561.00

Map

 Project objective

The main scope of LEONID project is the development and validation of the clinical performance of a new diagnostic Nanostring-based device against existing standards (FISH and IHC) for the detection of in vitro biomarkers with predictive power of response to tyrosin kinase inhibitors used for lung cancer treatment. The device will be the first CE-IVD kit that detects all ALK, ROS1 and RET rearrangements with known and unknown partners in one multiplex assay and that, at the same time, identify the main variants of EML4-ALK. The clinical validation will be extended to the associated software for secondary analysis of data that will guarantee the results standardization, avoiding any personal interpretation. The new diagnostic device-software combination, that passed the technical feasibility analysis and is ready for experimental verification, will be the easiest, cheapest, fastest and standardized solution for ALK, ROS1 and RET fusions detection without losing sensitivity, specificity, robustness and reproducibility. The end users will be all molecular pathology laboratories supporting hospitals where lung cancer patients are treated, that (are going to) perform the analysis of fusion genes and want to reduce hands-on-time, error rate, and costs, saving specialized technical expertise and increasing the throughput of biomarkers and samples. At least 85 European medium-high throughput labs running 450 lung samples per year can be considered as potential customers. For Diatech Pharmacogenetics, the new device will be complementary to the existing products for pharmacogenetics analysis in oncology and will boost the company’s approach of potential European distributors. GeneticLab can offer the test to low throughput labs and can speed up the entrance into the oncology business. BiMind can extend the panel of features of its proprietary oncology EHR dedicated to the analysis of laboratory tests’ results and can provide its new software through Diatech PGx or directly.

 Deliverables

List of deliverables.
Final event Documents, reports 2019-05-30 12:53:27

Take a look to the deliverables list in detail:  detailed list of LEONID deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEONID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEONID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

PREPARE (2016)

Preventing Respiratory Events through Proactive Assessment of Respiratory Effort

Read More  

ADVANTAGE (2015)

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach

Read More  

LASER-HISTO (2016)

In vivo histology using femtosecond laser multiphoton tomograph for the early diagnosis of skin cancer and corneal diseases while simultaneously reducing Europe’s health care costs

Read More